SCHEDULE 13G/A: Point72 Discloses Minor Beneficial Ownership in Whitehawk Therapeutics

Point72 Asset Management and its affiliates have filed an amended Schedule 13G, reporting beneficial ownership of 5,087 shares, representing 0% of Whitehawk Therapeutics, Inc.'s common stock.

Summary

• Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen filed an Amendment No. 1 to Schedule 13G regarding Whitehawk Therapeutics, Inc. (formerly Aadi Bioscience, Inc.).
• The filing reports an aggregate beneficial ownership of 5,087 shares of Whitehawk Therapeutics, Inc. common stock.
• This ownership represents 0% of the total class of securities.
• The shares are held by an investment fund managed by Point72 Asset Management.
• Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management, and Steven A. Cohen controls both entities.
• The reporting persons collectively hold shared voting power and shared dispositive power over all 5,087 shares.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing disclosing beneficial ownership and does not contain information that would significantly alter the company's outlook or valuation. The 0% ownership indicates a minimal stake.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of beneficial ownership by an institutional investor, Point72, in a publicly traded company, Whitehawk Therapeutics. It reflects a minor, non-controlling investment and does not inherently indicate broader industry trends or competitive positioning.

Key Dates

Keywords

Whitehawk Therapeutics, Point72 Asset Management, Schedule 13G, beneficial ownership, common stock, SEC filing, investment fund